GOUT
MCID: GT001
MIFTS: 58

Gout (GOUT) malady

Categories: Bone diseases, Genetic diseases, Neuronal diseases, Nephrological diseases, Metabolic diseases, Blood diseases, Rare diseases

Aliases & Classifications for Gout

Summaries for Gout

MedlinePlus : 41 gout is a common, painful form of arthritis. it causes swollen, red, hot and stiff joints. gout happens when uric acid builds up in your body. uric acid comes from the breakdown of substances called purines. purines are in your body's tissues and in foods, such as liver, dried beans and peas, and anchovies. normally, uric acid dissolves in the blood. it passes through the kidneys and out of the body in urine. but sometimes uric acid can build up and form needle-like crystals. when they form in your joints, it is very painful. the crystals can also cause kidney stones. often, gout first attacks your big toe. it can also attack ankles, heels, knees, wrists, fingers, and elbows. at first, gout attacks usually get better in days. eventually, attacks last longer and happen more often. you are more likely to get gout if you are a man have family member with gout are overweight drink alcohol eat too many foods rich in purines gout can be hard to diagnose. your doctor may take a sample of fluid from an inflamed joint to look for crystals. you can treat gout with medicines. pseudogout has similar symptoms and is sometimes confused with gout. however, it is caused by calcium phosphate, not uric acid. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Gout, also known as arthritis, gouty, is related to hprt-related gout and gout, hprt1-related, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Gout is HPRT1 (Hypoxanthine Phosphoribosyltransferase 1), and among its related pathways/superpathways are Purine metabolism (KEGG) and Purine metabolism (REACTOME). The drugs Febuxostat and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and skin, and related phenotypes are homeostasis/metabolism and adipose tissue

Disease Ontology : 12 An arthritis that has material basis in uric acid crystal deposits located in joint.

Wikipedia : 71 Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and... more...

Related Diseases for Gout

Diseases in the Gout family:

Hprt-Related Gout Gout, Hprt1-Related

Diseases related to Gout via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
id Related Disease Score Top Affiliating Genes
1 hprt-related gout 12.1
2 gout, hprt1-related 11.8
3 gout susceptibility 4 11.7
4 lesch-nyhan syndrome 11.7
5 phosphoribosylpyrophosphate synthetase superactivity 11.6
6 familial juvenile hyperuricaemic nephropathy 11.5
7 hyperuricemic nephropathy, familial juvenile 1 11.5
8 autosomal dominant medullary cystic kidney disease with hyperuricemia 11.3
9 arthritis 11.1
10 crystal arthropathies 11.1
11 nephronophthisis 11.1
12 chondrocalcinosis 2 11.0
13 autosomal dominant tubulointerstitial kidney disease, umod-related 10.9
14 medullary cystic kidney disease 2 10.7
15 nephronophthisis-like nephropathy 1 10.7
16 occipital neuralgia 10.7
17 autosomal dominant medullary cystic kidney disease without hyperuricemia 10.7
18 hyperuricemia 10.5
19 spinocerebellar ataxia 5 10.3 HPRT1 SLC22A12 SLC2A9
20 glomerulocystic kidney disease with hyperuricemia and isosthenuria 10.2 HPRT1 SLC22A12 UMOD
21 dent disease 2 10.2 APRT HPRT1
22 arts syndrome 10.2 HPRT1 PRPS1
23 lattice corneal dystrophy type ii 10.2 APRT XDH
24 meier-gorlin syndrome 4 10.2 APRT HPRT1 XDH
25 noonan syndrome 9 10.2 APRT HPRT1 PRPS1
26 intussusception 10.2 IL1B TNF
27 mitochondrial dna depletion syndrome 6 10.1 APRT UMOD XDH
28 epileptic encephalopathy, early infantile, 8 10.1 ADSL HPRT1 PRPS1
29 tau syndrome 10.1 IL1B TNF
30 newborn respiratory distress syndrome 10.1 APRT HPRT1 UMOD XDH
31 ovarian mucinous adenocarcinoma 10.1 ABCG2 IL1B TNF
32 hypotrichosis-lymphedema-telangiectasia-renal defect syndrome 10.1 IL1B TNF
33 kidney disease 10.0
34 arthropathy 10.0
35 stocco dos santos syndrome 10.0 IL1B TNF
36 posterior foramen magnum meningioma 10.0 ADSL APRT HPRT1 XDH
37 combined oxidative phosphorylation deficiency 6 10.0 ADSL APRT HPRT1 XDH
38 warthin tumor 9.9 IL1B NLRP3 TNF
39 meier-gorlin syndrome 3 9.9 IL1B NLRP3 TNF
40 persistent hyperplastic primary vitreous, autosomal recessive 9.9 CARMIL1 HPRT1 SLC22A12 XDH
41 senile reticular retinal degeneration 9.9 IL1B NLRP3 TNF
42 gonococcal endophthalmia 9.9 IL1B NLRP3 TNF
43 rheumatoid arthritis 9.9
44 pyloric stenosis, infantile hypertrophic, 2 9.9 IL1B NLRP3 TNF
45 skin conditions 9.9 IL1B NLRP3 TNF
46 baritosis 9.9 IL1B NLRP3 TNF
47 senile cataract 9.9 IL1B NLRP3 TNF
48 atherosclerosis 9.9
49 nephrolithiasis 9.8
50 obesity 9.8

Comorbidity relations with Gout via Phenotypic Disease Network (PDN): (show all 27)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Benign Essential Hypertension
Bladder Neck Obstruction Bronchitis
Chronic Kidney Failure Chronic Myocardial Ischemia
Deficiency Anemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Ischemic Heart Disease
Kidney Disease Left Ventricular Outflow Tract Obstruction
Mitral Valve Disease Osteoarthritis
Peripheral Vascular Disease Prostate Cancer
Prostatic Hypertrophy Sinoatrial Node Disease
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Gout:



Diseases related to Gout

Symptoms & Phenotypes for Gout

UMLS symptoms related to Gout:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Gout:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.7 XDH ABCG2 APRT HPRT1 IL1B NLRP3
2 adipose tissue MP:0005375 9.63 ABCG2 PRKG2 SLC2A9 TNF UMOD XDH
3 renal/urinary system MP:0005367 9.23 ABCG2 APRT HPRT1 NLRP3 SLC22A12 SLC2A9

Drugs & Therapeutics for Gout

Drugs for Gout (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1 144060-53-7 134018
2
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2 10102-43-9 145068
3
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
4
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-86-8 6167 2833
5
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
6
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
7
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22204-53-1 1302 156391
8
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
9
Codeine Approved, Illicit Phase 4 76-57-3 5284371
10
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
11
Tramadol Approved, Investigational Phase 4,Phase 1,Phase 2 27203-92-5 33741
12
Amitriptyline Approved Phase 4 50-48-6 2160
13
Cyclobenzaprine Approved Phase 4 303-53-7 2895
14
Hydrocodone Approved, Illicit Phase 4 125-29-1 5284569
15
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1 76-42-6 5284603
16
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
17
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-78-2 2244
18
Capsaicin Approved Phase 4 404-86-4 1548943
19
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-86-1 3715
20
Nitroprusside Approved Phase 4 15078-28-1 11963622
21
Allopurinol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 315-30-0 2094
22
Probenecid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-66-9 4911
23
Sumatriptan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 103628-46-2 5358
24
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1 15687-27-1 3672
25
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757 53477783
26
Ketorolac Approved Phase 4,Phase 3 74103-06-3, 66635-83-4 3826
27
Nifedipine Approved Phase 4,Phase 3,Phase 2 21829-25-4 4485
28
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
29
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2 15307-86-5 3033
30
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
31
Etoricoxib Approved, Investigational Phase 4,Phase 3 202409-33-4 123619
32
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
33
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134774-45-1
34
Theophylline Approved Phase 4,Phase 1 58-55-9 2153
35
Coal tar Approved Phase 4,Phase 3 8007-45-2
36
Dipyridamole Approved Phase 4 58-32-2 3108
37
Oseltamivir Approved Phase 4,Phase 1 204255-11-8, 196618-13-0 65028
38
Diazepam Approved, Illicit, Vet_approved Phase 4 439-14-5 3016
39
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
40
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
41
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
42
Morphine Approved, Investigational Phase 4 57-27-2 5288826
43
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
44
Meloxicam Approved, Vet_approved Phase 4,Phase 3,Phase 2 71125-38-7 5281106 54677470
45
Dinoprostone Approved Phase 4,Phase 3 363-24-6 5280360
46
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
47
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
48
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
49
Diphenhydramine Approved Phase 4,Phase 3,Phase 2,Phase 1 58-73-1, 147-24-0 3100
50
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681

Interventional clinical trials:

(show top 50) (show all 777)
id Name Status NCT ID Phase
1 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4
2 Post-MI PET Scan Imaging of Inflammation Unknown status NCT02281305 Phase 4
3 Colchicine in ST-elevation Myocardial Infarction Unknown status NCT01936285 Phase 4
4 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4
5 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
6 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4
7 Postoperative Analgesia in Laminectomy Unknown status NCT02255955 Phase 4
8 Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain on Postoperative Pain Unknown status NCT02252614 Phase 4
9 A Randomized Study of Three Medication Regimens for Acute Low Back Pain Unknown status NCT01587274 Phase 4
10 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4
11 Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers Unknown status NCT00152724 Phase 4
12 Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout Completed NCT00170781 Phase 4
13 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4
14 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed NCT01988402 Phase 4
15 Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout Completed NCT01310673 Phase 4
16 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol Completed NCT01451645 Phase 4
17 Colchicine Or Naproxen Treatment for ACute gouT Completed NCT01994226 Phase 4
18 A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) Completed NCT00142558 Phase 4
19 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed NCT01112982 Phase 4
20 Allopurinol Outcome Study Completed NCT01391325 Phase 4
21 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4
22 Optimal Administration of Allopurinol in Dialysis Patients Completed NCT02477488 Phase 4
23 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4
24 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Completed NCT01472692 Phase 4
25 Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM Completed NCT01529099 Phase 4
26 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4
27 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4
28 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4
29 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4
30 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4
31 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4
32 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4
33 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4
34 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4
35 Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee Completed NCT00443092 Phase 4
36 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4
37 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4
38 Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion Completed NCT02752633 Phase 4
39 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4
40 Anti-platelet Effects of Colchicine in Healthy Volunteers Completed NCT02140372 Phase 4
41 Colchicine in Coronary Artery Bypass Graft (CABG) Completed NCT02122484 Phase 4
42 Drug Interaction Study of Colchicine and Theophylline Completed NCT01601132 Phase 4
43 Cochicine Treatment for Post- Operative Pericardial Effusion Completed NCT01266694 Phase 4
44 A Pilot Study for PK/PD Parameter of Colchicine in Chronic Kidney Disease Patient. Completed NCT01173107 Phase 4
45 Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) Completed NCT01084278 Phase 4
46 Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain Completed NCT00917436 Phase 4
47 EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes Completed NCT00272532 Phase 4
48 Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment. Completed NCT00235079 Phase 4
49 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4
50 Allopurinol in Chronic Heart Failure Completed NCT00997542 Phase 4

Search NIH Clinical Center for Gout

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: gout

Genetic Tests for Gout

Anatomical Context for Gout

MalaCards organs/tissues related to Gout:

39
Kidney, Liver, Skin, Heart, Bone, Neutrophil, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Gout:

18
Joint

Publications for Gout

Articles related to Gout:

(show top 50) (show all 971)
id Title Authors Year
1
Dietary Management of Gout: What is the Evidence? ( 27986240 )
2017
2
Risk of Colchicine-Associated Myopathy in Gout: Influence of Concomitant Use of Statin. ( 28065770 )
2017
3
Racial differences in health-related quality of life and functional ability in patients with gout. ( 28028159 )
2017
4
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment. ( 28074640 )
2017
5
Oral delivery of allopurinol niosomes in treatment of gout in animal model. ( 28067087 )
2017
6
Erratum to: Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. ( 28004165 )
2017
7
Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. ( 28089200 )
2017
8
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. ( 27899376 )
2017
9
Assessing Elementary Lesions in Gout by Ultrasound: Results of an OMERACT Patient-based Agreement and Reliability Exercise. ( 28042133 )
2017
10
Gout in immigrant groups: a cohort study in Sweden. ( 28091806 )
2017
11
Gout (1st Edition). ( 28042131 )
2017
12
Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. ( 27225847 )
2016
13
Why better treatment of gout is needed. ( 27586807 )
2016
14
The management of gout: Much has changed. ( 27166465 )
2016
15
Prednisolone was equivalent to indomethacin for pain reduction in acute gout. ( 27182917 )
2016
16
Spatiotemporal gait parameters and plantar pressure distribution during barefoot walking in people with gout and asymptomatic hyperuricemia: comparison with healthy individuals with normal serum urate concentrations. ( 27134680 )
2016
17
Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. ( 27650765 )
2016
18
Ultrasound features of the first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia: Comparison with normouricaemic individuals. ( 27635596 )
2016
19
Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study. ( 27134260 )
2016
20
WDR1 and CLNK gene polymorphisms correlate with serum glucose and high-density lipoprotein levels in Tibetan gout patients. ( 26438387 )
2016
21
Sialosis, Gout Induced or Idiopathic? Case Report. ( 27663535 )
2016
22
Association between Gout and Erectile Dysfunction: A Systematic Review and Meta-Analysis. ( 28036397 )
2016
23
Cytokine Profile in Gout: Inflammation Driven by IL-6 and IL-18? ( 27219123 )
2016
24
Lesinurad (Zurampic) for gout-associated hyperuricemia. ( 27849193 )
2016
25
Urate crystal deposition and bone erosion in gout: 'inside-out' or 'outside-in'? A dual-energy computed tomography study. ( 27629724 )
2016
26
Nephrolithiasis among male patients with newly diagnosed gout. ( 27609977 )
2016
27
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. ( 28040245 )
2016
28
Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout. ( 26410617 )
2016
29
Genetic variation in WDR1 is associated with gout risk and gout-related metabolic indices in the Han Chinese population. ( 27173277 )
2016
30
Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. ( 27138165 )
2016
31
The risk of atrial fibrillation in patients with gout: a nationwide population-based study. ( 27599578 )
2016
32
Crystal arthritis: Apolipoprotein gene variants-causal role in gout? ( 27150667 )
2016
33
Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer? ( 28039184 )
2016
34
Clinical Diagnosis of Gout Without Joint Aspirate. ( 27637128 )
2016
35
Clinical Inquiry: How do clinical prediction rules compare with joint fluid analysis in diagnosing gout? ( 28087872 )
2016
36
Gout and African Americans: Reducing disparities. ( 27618355 )
2016
37
Pancreatic gout and the role of multimodality imaging in its management. ( 27190122 )
2016
38
Gout and Risk of Fracture in Women: A Prospective Cohort Study. ( 27589491 )
2016
39
A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia. ( 27153502 )
2016
40
Severe tophaceous gout and disability: changes in the past 15A years. ( 27631961 )
2016
41
PDK2 and ABCG2 genes polymorphisms are correlated with blood glucose levels and uric acid in Tibetan gout patients. ( 26909964 )
2016
42
Expert's comment concerning Grand Rounds case entitled "Tophaceous gout of the lumbar spine mimicking a spinal meningioma" by Pedro Ribeiro da Cunha Ferreira, AntA^nio Judice Peliz, and Marcos Barbosa (Eur Spine J, 2016; DOI 10.1007/s00586-016-4831-7). ( 27858235 )
2016
43
Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient. ( 27200198 )
2016
44
Risk of acute gout among active smokers: data from nationwide inpatient sample. ( 27658418 )
2016
45
Genetic Analysis of IL-17 Gene Polymorphisms in Gout in a Male Chinese Han Population. ( 26890073 )
2016
46
ALPK1 phosphorylates myosin IIA modulating TNF-I+ trafficking in gout flares. ( 27169898 )
2016
47
Gout mimicking rheumatoid arthritis. ( 27660106 )
2016
48
Treat-to-target (T2T) recommendations for gout. ( 27658678 )
2016
49
Chronic tophaceous gout with multiple large tophi. ( 27600162 )
2016
50
Tophaceous gout in a female premenopausal patient with an unexpected diagnosis of glycogen storage disease type Ia: a case report and literature review. ( 27139513 )
2016

Variations for Gout

Expression for Gout

Search GEO for disease gene expression data for Gout.

Pathways for Gout

Pathways related to Gout according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.29 ADSL APRT HPRT1 PRPS1 XDH
2
Show member pathways
12.01 ADSL APRT HPRT1 XDH
3 11.46 IL1B NLRP3 TNF
4 10.92 ABCG2 IL1B TNF
5 10.76 ABCG2 SLC22A11
6 10.76 HPRT1 PRPS1 XDH
7 10.64 IL1B TNF
8 10.41 ADSL HPRT1 PRPS1
9 10.18 ABCG2 SLC17A1 SLC17A3 SLC22A11 SLC22A12 SLC2A9

GO Terms for Gout

Cellular components related to Gout according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.17 ABCG2 PRKG2 SLC17A3 SLC22A11 SLC22A12 SLC2A9

Biological processes related to Gout according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.8 ABCG2 SLC16A9 SLC17A1 SLC17A3 SLC22A11 SLC22A12
2 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 NLRP3 TNF XDH
3 phosphate ion transmembrane transport GO:0035435 9.63 SLC17A1 SLC17A3
4 negative regulation of lipid catabolic process GO:0050995 9.63 IL1B TNF
5 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IL1B TNF
6 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.62 IL1B TNF
7 grooming behavior GO:0007625 9.61 APRT HPRT1
8 purine-containing compound salvage GO:0043101 9.61 APRT HPRT1
9 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 IL1B TNF
10 positive regulation of chemokine biosynthetic process